DARZALEX® SC

Efficacy

Efficacy

Comparable efficacy with DARZALEX® IV[1][2][3][4][5]

Safety

Safety Profile

Similar safety to DARZALEX® IV, with fewer and less severe IRRs[1][5]

Convenience

Convenience

3–5-minute injection from the first dose in new patients, and from the next scheduled dose in patients who are currently on DARZALEX® IV[1]

simplicity

Simplicity

Single fixed dose reduces preparation time and wastage. Available across all approved DARZALEX® IV indications, with no changes to treatment schedules[1]

Patient Experience

Patient experience

Patients receiving DARZALEX® subcutaneously are more satisfied with their therapy than those who receive it as an IV infusion[5]

DARZALEX® SC practical guidance
DARZALEX® SC handling and administration

An interactive video covering the key facts about the handling, preparation and administration of DARZALEX® SC, including a step-by-step demonstration of the subcutaneous administration. The interactive video allows you to easily navigate around different topics of interest, including dosing, administration, AE management, and guidance on clinic and practice changes when going from IV infusions to SC injections.

DARZALEX® SC studies
DARZALEX® SC STUDIES

In this interactive video, Prof. Mateos gives an overview of the DARZALEX® SC PAVO, COLUMBA and PLEIADES studies. Use the video’s navigation tool to access topics of interest, including study designs, efficacy, safety, and Q&A with Prof. Mateos, where she provides her expert opinion on the integration of DARZALEX® SC into clinical practice based on her experience from clinical trials.

Resources

Practicalities
Practical guidance for transitioning to DARZALEX® SC

Download or request copies of the practical guide for using daratumumab SC, MDT practicalities slide deck and in-clinic handling and administration poster

AE: adverse event

ISR: injection-site reaction

IV: intravenous

MDT: multidisciplinary team

SC: subcutaneous

Titular da Autorização de Introdução no Mercado: Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Bélgica.
Para mais informações deverá contactar o Representante do Titular da Autorização de Introdução no Mercado: Janssen-Cilag Farmacêutica, Lda.

Medicamento de receita médica restrita, de utilização reservada a certos meios especializados.

Antes de prescrever consulte o RCM completo.

RCM de Darzalex®, veja aqui